DelveInsight’s ‘ Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Progressive Supranuclear Palsy market report provides analysis regarding current treatment practices, emerging drugs like AZP2006, UCB0107, RT001 and other promising candidates like NBMIand Antisense oligonucleotide market share of the individual therapies, and historical, current and forecasted Progressive Supranuclear Palsy market size from 2017 to 2030, segmented by seven major markets.
The report also covers current Progressive Supranuclear Palsy treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Progressive supranuclear palsy (PSP) is an uncommon degenerative neurological disorder—the disease results from damage to nerve cells in the brain—that causes the gradual deterioration of balance and walking; speech difficulties, trouble in swallowing, diminished vision, changes in mood and behavior, and cognitive impairment. The disorder’s long name indicates that the disease worsens (progressive) and causes weakness (palsy) by damaging certain parts of the brain above nerve cell clusters called nuclei (supranuclear). These nuclei mainly control eye movements.
One of the classic signs of the disease is an inability to aim and move the eyes properly, which individuals may experience as blurring of vision. While the pattern of signs and symptoms can be quite different from person to person, the most frequent first symptom of PSP is a loss of balance while walking.
It was sometimes referred to as Steele–Richardson–Olszewski syndrome, reflecting the combined names of the scientists who defined the disorder. Progressive supranuclear palsy is characterized pathologically by four-repeat (4R) Tau deposition in various cell types and anatomical regions. The broad spectrum of syndromes that have been linked to PSP pathology also includes PSP-parkinsonism, a variant that presents with features suggestive of Parkinson’s disease (PD), pure akinesia with gait freezing, corticobasal syndrome, non-fluent variant primary progressive aphasia, behavioural variant frontotemporal dementia and even PSP presenting with cerebellar ataxia.
No specific laboratory tests or imaging approaches currently exist to diagnose PSP definitively. The disease is often difficult to diagnose because its symptoms can be very much like those of other movement disorders, and because some of the most characteristic symptoms may develop late or not at all. While there is currently no disease-modifying therapy for PSP, some treatment strategies have been successful for symptomatic management.
The most frequently prescribed medications for symptomatic management were drugs for movement disorders, anti-infectants, and anti-depressants. This chapter covers the details of conventional and current medical therapies available for the treatment of Progressive Supranuclear Palsy. It also provides Progressive Supranuclear Palsy treatment guidelines across the United States and Europe.
DelveInsight’s Progressive Supranuclear Palsy market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, neurobiology, biomarkers and diagnosis. It also provides Progressive Supranuclear Palsy treatment pattern and treatment guidelines in the US and Europe. The market size of Progressive Supranuclear Palsy is expected to increase at a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounted for the largest Progressive Supranuclear Palsy market size followed by Japan. Among the EU5 countries, the United Kingdom had the largest market size, with USD 0.70 million in 2017 while Spain had the smallest market size of PSP, with USD 0.24 million in 2017.
This section focuses on the rate of uptake of the potential drugs in the Progressive Supranuclear Palsy market or expected to get launched in the market during the study period 2017–2030. The analysis covers Progressive Supranuclear Palsy market uptake by drugs; patient uptake by therapies; and sale of each drug. It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size.
All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. The dynamics of PSP market is anticipated to experience a major positive shift in the coming years owing to the expected launch of therapies like AZP2006, UCB0107 and RT001.
Comments